key personnel.
These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2010, our Form 10-Q for the quarter ended March 31, 2011, and our Form 10-Q for the quarter ended June 30, 2011. CryoLife does not undertake to update its forward-looking statements.CRYOLIFE, INC. AND SUBSIDIARIES
Financial Highlights(In thousands, except per share data)Three Months EndedNine Months EndedSeptember 30,September 30,2011201020112010(Unaudited)
(Unaudited)Revenues:Preservation services
$ 14,656
$ 15,111
$ 45,018
$ 45,699Products
14,923
13,175
43,932
41,276Other
75
157
279
448Total revenues29,65428,44389,22987,423Cost of preservation services and products:Preservation services
8,349
8,911
25,709
27,322Products
2,393
4,310
7,051
9,318Total cost of preservation services and products10,74213,22132,76036,640Gross margin18,91215,22256,46950,783Operating expenses:General, administrative, and marketing
14,726
11,376
42,676
36,863Research and development
1,690
1,590
5,099
4,122Acquired in-process research and development
--
3,513
--
3,513Total operating expenses16,41616,47947,77544,498Operating income (loss)2,496(1,257)8,6946,285Interest expense
49
29
116
145Interest income
(1)
(6)
(13)
(16)Gain on valuation of derivative
--
(143)
--
(1,345)Other than temporary investment impairment
--
3,638
--
3,638Other expense (income), net
159
(187)
(12)
44Income (loss) before income taxes2,289(4,588)8,6033,819Income tax expense (benefit)
270
(1,557)
3,0
'/>"/>
SOURCE CryoLife, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Related medicine technology :1.
CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic2.
CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)3.
CryoLife Reports Record Quarterly Revenues of $28.2 Million4.
CryoLife to Present at Upcoming Investor Conferences in New York5.
CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference6.
CryoLife Provides Initial 2010 Financial Guidance7.
CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent8.
CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive9.
CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results10.
CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe11.
CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference